Primary cardiac sarcoma: A novel treatment approach

Benjamin Movsas, Julie Teruya-Feldstein, Judy Smith, Eli Glatstein, Alan H. Epstein

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Primary cardiac sarcomas carry a dismal prognosis with no known curative therapy using standard treatment approaches. By its very location, the possibility of a radical complete resection-the underlying principle in the management of any soft-tissue sarcoma-is precluded. While literally in a continuous 'blood bath,' cardiac sarcomas are associated with a very high rate of hematogenous metastases. This report describes the management of a ease in a 51-year-old white man with a high-grade unresectable cardiac sarcoma who was treated with hyperfractionated (twice daily) radiotherapy to a total dose of 7,050 cGy along with a radiosensitizer, (5'-iododeoxyuridine. The patient currently is disease-free and functioning well more than 5 years following this novel treatment approach.

Original languageEnglish
Pages (from-to)648-652
Number of pages5
Issue number2
StatePublished - 1998
Externally publishedYes


  • Cardiac sarcoma
  • Hyperfractionation
  • Radiosensitization
  • Radiotherapy


Dive into the research topics of 'Primary cardiac sarcoma: A novel treatment approach'. Together they form a unique fingerprint.

Cite this